Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Samuel Jacob Klempner, M.D.


Hamilton College, Clinton, NYBA2003Biology
UMASS Medical School, Worcester, MAMD2007Medicine
Brigham and Women's Hospital, Boston, MA2010Internal Medicine
Beth Israel Deaconess Med Ctr, Boston, MA2013Oncology


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski LA, Michel AG, Syed MU, Fella KA, Sakhi M, Baiev I, Juric D, Gainor JF, Klempner SJ, Lennerz JK, Siravegna G, Bar-Peled L, Hata AN, Heist RS, Corcoran RB. Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. Cancer Discov. 2021 Apr 06. PMID: 33824136.
    Citations:    Fields:    
  2. Loaiza-Bonilla A, Benson AB, Grothey A, Karimi M, Klempner SJ, Lin D, Mahtani R, Soares HP. Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group. Oncologist. 2021 Mar 02. PMID: 33650740.
    Citations:    Fields:    
  3. Dowlati A, Harvey RD, Carvajal RD, Hamid O, Klempner SJ, Kauh JSW, Peterson DA, Yu D, Chapman SC, Szpurka AM, Carlsen M, Quinlan T, Wesolowski R. LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial. Invest New Drugs. 2021 Feb 23. PMID: 33624233.
    Citations:    Fields:    
  4. Klempner SJ, Ryan DP. HIPEC for colorectal peritoneal metastases. Lancet Oncol. 2021 02; 22(2):162-164. PMID: 33476594.
    Citations:    Fields:    Translation:Humans
  5. Li SS, Klempner SJ, Costantino CL, Parikh A, Clark JW, Wo JY, Hong TS, Mullen JT. Impact of Treatment Sequencing on Survival for Patients with Locally Advanced Gastric Cancer. Ann Surg Oncol. 2021 May; 28(5):2856-2865. PMID: 33393043.
    Citations: 1     Fields:    
  6. van Seventer EE, Fish MG, Fosbenner K, Kanter K, Mojtahed A, Allen JN, Blaszkowsky L, Clark JW, Dubois J, Franses JW, Giantonio BJ, Goyal L, Klempner SJ, Roeland EJ, Ryan DP, Weekes CD, Mulvey T, El-Jawahri A, Horick N, Corcoran RB, Parikh AR, Nipp RD. Associations of baseline patient-reported outcomes with treatment outcomes in advanced gastrointestinal cancer. Cancer. 2021 Feb 15; 127(4):619-627. PMID: 33170962.
    Citations:    Fields:    
  7. Klempner SJ, Upadhyay V, Chao J. A Space-Time Continuum for Immunotherapy Biomarkers in Gastroesophageal Cancer? Clin Cancer Res. 2020 Dec 15; 26(24):6401-6403. PMID: 33023951.
    Citations:    Fields:    
  8. Kim S, DiPeri TP, Guan M, Placencio-Hickok VR, Kim H, Liu JY, Hendifar A, Klempner SJ, Nipp R, Gangi A, Burch M, Waters K, Cho M, Chao J, Atkins K, Kamrava M, Tuli R, Gong J. Impact of palliative therapies in metastatic esophageal cancer patients not receiving chemotherapy. World J Gastrointest Surg. 2020 Sep 27; 12(9):377-389. PMID: 33024512.
  9. Chaudhary SP, Kwak EL, Hwang KL, Lennerz JK, Corcoran RB, Heist RS, Russo AL, Parikh A, Borger DR, Blaszkowsky LS, Faris JE, Murphy JE, Azzoli CG, Roeland EJ, Goyal L, Allen J, Mullen JT, Ryan DP, Iafrate AJ, Klempner SJ, Clark JW, Hong TS. Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers. Oncologist. 2020 11; 25(11):e1691-e1700. PMID: 32820577.
    Citations: 1     Fields:    
  10. Reynolds KL, Klempner SJ, Parikh A, Hochberg EP, Michaelson MD, Mooradian MJ, Lee RJ, Soumerai TE, Hobbs G, Piotrowska Z, Sykes DB, Farago AF, Bardia A, Rosovsky RP, Ryan DP. The Art of Oncology: COVID-19 Era. Oncologist. 2020 11; 25(11):997-1000g. PMID: 32697887.
    Citations:    Fields:    Translation:Humans
  11. Guo Y, Guo XL, Wang S, Chen X, Shi J, Wang J, Wang K, Klempner SJ, Wang W, Xiao M. Genomic Alterations of NTRK, POLE, ERBB2, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer. Oncologist. 2020 11; 25(11):e1671-e1680. PMID: 32627883.
    Citations: 1     Fields:    
  12. Jeon CY, Lin YC, Klempner SJ, Wu BU, Kim S, Waters KM, Haile RW. Endoscopic History and Provider Characteristics Influence Gastric Cancer Survival in Asian Americans. Cancer Prev Res (Phila). 2020 09; 13(9):773-782. PMID: 32561562.
    Citations:    Fields:    
  13. Wall JA, Klempner SJ, Arend RC. The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer. Expert Opin Investig Drugs. 2020 Jul; 29(7):639-644. PMID: 32408777.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  14. Pan J, Silva TC, Gull N, Yang Q, Plummer JT, Chen S, Daigo K, Hamakubo T, Gery S, Ding LW, Jiang YY, Hu S, Xu LY, Li EM, Ding Y, Klempner SJ, Gayther SA, Berman BP, Koeffler HP, Lin DC. Lineage-Specific Epigenomic and Genomic Activation of Oncogene HNF4A Promotes Gastrointestinal Adenocarcinomas. Cancer Res. 2020 07 01; 80(13):2722-2736. PMID: 32332020.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  15. Chao J, Bedell V, Lee J, Li MS, Chu P, Yuan YC, Zhao D, Klempner SJ, Lin RJ. Association Between Spatial Heterogeneity Within Nonmetastatic Gastroesophageal Adenocarcinomas and Survival. JAMA Netw Open. 2020 04 01; 3(4):e203652. PMID: 32338752.
    Citations: 1     Fields:    Translation:Humans
  16. Chao J, Lee J, Kim K, Kang SY, Lee T, Kim KM, Kim ST, Klempner SJ, Lee H. A Pilot Study of Baseline Spatial Genomic Heterogeneity in Primary Gastric Cancers Using Multi-Region Endoscopic Sampling. Front Oncol. 2020; 10:225. PMID: 32158697.
  17. Hur JY, Chao J, Kim K, Kim ST, Kim KM, Klempner SJ, Lee J. High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers. Pathol Res Pract. 2020 Apr; 216(4):152878. PMID: 32089408.
    Citations: 1     Fields:    Translation:Humans
  18. Li SS, Udelsman BV, Parikh A, Klempner SJ, Clark JW, Roeland EJ, Wo JY, Hong TS, Mullen JT. Impact of Postoperative Complication and Completion of Multimodality Therapy on Survival in Patients Undergoing Gastrectomy for Advanced Gastric Cancer. J Am Coll Surg. 2020 06; 230(6):912-924. PMID: 32035978.
    Citations: 2     Fields:    Translation:Humans
  19. Chao J, Mehta A, Klempner SJ. Bringing Personalized Medicine to Precision Medicine in Gastroesophageal Cancer. JAMA Netw Open. 2020 02 05; 3(2):e1921289. PMID: 32058546.
    Citations:    Fields:    Translation:Humans
  20. Chorath J, Placencio-Hickok VR, Guan M, Nissen N, Kamrava M, Klempner SJ, Nassir Y, Hendifar A, Gong J. Durable Response to Carboplatin, Etoposide, Nivolumab, and Ipilimumab in Metastatic High-Grade Neuroendocrine Carcinoma of the Gallbladder. Pancreas. 2020 02; 49(2):e19-e20. PMID: 32049953.
    Citations:    Fields:    Translation:Humans
  21. Klempner SJ, Hata AN. Can the Help Match the Hype? KRASG12C-Specific Inhibitors and Beyond. Cancer Discov. 2020 01; 10(1):20-22. PMID: 31919120.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  22. Gao Y, Xi H, Wei B, Cui J, Zhang K, Li H, Cai A, Shen W, Li J, Rosell R, Chao J, Chen T, Klempner S, Qiao Z, Chen L. Association Between Liquid Biopsy and Prognosis of Gastric Cancer Patients: A Systematic Review and Meta-Analysis. Front Oncol. 2019; 9:1222. PMID: 31850190.
    Citations: 4     
  23. Klempner SJ, Hata AN. Sequence, Treat, Repeat: Addressing Resistance in EGFR-Mutant NSCLC. J Thorac Oncol. 2019 11; 14(11):1875-1877. PMID: 31668312.
    Citations:    Fields:    Translation:Humans
  24. Zhu VW, Klempner SJ, Ou SI. Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer. Trends Cancer. 2019 11; 5(11):677-692. PMID: 31735287.
    Citations: 3     Fields:    Translation:Humans
  25. Disel U, Madison R, Abhishek K, Chung JH, Trabucco SE, Matos AO, Frampton GM, Albacker LA, Reddy V, Karadurmus N, Benson A, Webster J, Paydas S, Cabanillas R, Nangia C, Ozturk MA, Millis SZ, Pal SK, Wilky B, Sokol ES, Gay LM, Soman S, Ganesan S, Janeway K, Stephens PJ, Zhu VW, Ou SI, Lovly CM, Gounder M, Schrock AB, Ross JS, Miller VA, Klempner SJ, Ali SM. The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. Oncologist. 2020 01; 25(1):e39-e47. PMID: 31604903.
    Citations: 2     Fields:    Translation:Humans
  26. Klempner SJ, Fabrizio D, Bane S, Reinhart M, Peoples T, Ali SM, Sokol ES, Frampton G, Schrock AB, Anhorn R, Reddy P. Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. Oncologist. 2020 01; 25(1):e147-e159. PMID: 31578273.
    Citations: 12     Fields:    Translation:Humans
  27. Gong J, Robertson MD, Kim E, Fakih M, Schrock AB, Tam KW, Burugapalli B, Monjazeb AM, Hendifar AE, Hitchins M, Klempner SJ, Cho M. Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden. Clin Colorectal Cancer. 2019 12; 18(4):307-309. PMID: 31563511.
    Citations: 1     Fields:    Translation:Humans
  28. Chuang J, Chao J, Hendifar A, Klempner SJ, Gong J. Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies. Transl Gastroenterol Hepatol. 2019; 4:63. PMID: 31559344.
    Citations: 4     
  29. Chen L, Huang M, Plummer J, Pan J, Jiang YY, Yang Q, Silva TC, Gull N, Chen S, Ding LW, An O, Yang H, Cheng Y, Said JW, Doan N, Dinjens WN, Waters KM, Tuli R, Gayther SA, Klempner SJ, Berman BP, Meltzer SJ, Lin DC, Koeffler HP. Master transcription factors form interconnected circuitry and orchestrate transcriptional networks in oesophageal adenocarcinoma. Gut. 2020 04; 69(4):630-640. PMID: 31409603.
    Citations: 7     Fields:    Translation:HumansCells
  30. Klempner SJ, Wainberg ZA. Ramucirumab plus pembrolizumab: can we make the maths work? Lancet Oncol. 2019 08; 20(8):1041-1043. PMID: 31301961.
    Citations:    Fields:    Translation:Humans
  31. Schrock AB, Ouyang C, Sandhu J, Sokol E, Jin D, Ross JS, Miller VA, Lim D, Amanam I, Chao J, Catenacci D, Cho M, Braiteh F, Klempner SJ, Ali SM, Fakih M. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019 07 01; 30(7):1096-1103. PMID: 31038663.
    Citations: 68     Fields:    Translation:Humans
  32. Klempner SJ, Madison R, Pujara V, Ross JS, Miller VA, Ali SM, Schrock AB, Kim ST, Maron SB, Dayyani F, Catenacci DVT, Lee J, Chao J. FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. Oncologist. 2019 11; 24(11):1462-1468. PMID: 31249137.
    Citations: 1     Fields:    Translation:Humans
  33. Ang C, Klempner SJ, Ali SM, Madison R, Ross JS, Severson EA, Fabrizio D, Goodman A, Kurzrock R, Suh J, Millis SZ. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget. 2019 Jun 18; 10(40):4018-4025. PMID: 31258846.
    Citations: 16     Fields:    
  34. Zhao D, Klempner SJ, Chao J. Progress and challenges in HER2-positive gastroesophageal adenocarcinoma. J Hematol Oncol. 2019 05 17; 12(1):50. PMID: 31101074.
    Citations: 7     Fields:    Translation:HumansAnimals
  35. Catenacci DVT, Hochster H, Klempner SJ. Keeping Checkpoint Inhibitors in Check. JAMA Netw Open. 2019 05 03; 2(5):e192546. PMID: 31050772.
    Citations: 2     Fields:    Translation:Humans
  36. Parikh AR, He Y, Hong TS, Corcoran RB, Clark JW, Ryan DP, Zou L, Ting DT, Catenacci DV, Chao J, Fakih M, Klempner SJ, Ross JS, Frampton GM, Miller VA, Ali SM, Schrock AB. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. Oncologist. 2019 10; 24(10):1340-1347. PMID: 31040255.
    Citations: 14     Fields:    Translation:Humans
  37. Lee J, Singh A, Ali SM, Lin DI, Klempner SJ. TNS1-ALK Fusion in a Recurrent, Metastatic Uterine Mesenchymal Tumor Originally Diagnosed as Leiomyosarcoma. Acta Med Acad. 2019 Apr; 48(1):116-120. PMID: 31264439.
    Citations: 2     Fields:    Translation:Humans
  38. Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology. 2019 06; 156(8):2242-2253.e4. PMID: 30836094.
    Citations: 35     Fields:    Translation:Humans
  39. Klempner SJ, Catenacci DVT. Variety Is the Spice of Life, but Maybe Not in Gastroesophageal Adenocarcinomas. Cancer Discov. 2019 02; 9(2):166-168. PMID: 30737213.
    Citations: 2     Fields:    Translation:Humans
  40. Tuli R, Shiao SL, Nissen N, Tighiouart M, Kim S, Osipov A, Bryant M, Ristow L, Placencio-Hickok V, Hoffman D, Rokhsar S, Scher K, Klempner SJ, Noe P, Davis MJ, Wachsman A, Lo S, Jamil L, Sandler H, Piantadosi S, Hendifar A. A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. EBioMedicine. 2019 Feb; 40:375-381. PMID: 30635165.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  41. Klempner SJ, Bhangoo MS, Luu HY, Kim ST, Chao J, Kim KM, Lee J. Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy. J Gastrointest Oncol. 2018 Dec; 9(6):1198-1206. PMID: 30603142.
  42. Klempner SJ, Maron SB, Chase L, Lomnicki S, Wainberg ZA, Catenacci DVT. Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis. Oncologist. 2019 04; 24(4):475-482. PMID: 30470690.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  43. Fabrizio DA, George TJ, Dunne RF, Frampton G, Sun J, Gowen K, Kennedy M, Greenbowe J, Schrock AB, Hezel AF, Ross JS, Stephens PJ, Ali SM, Miller VA, Fakih M, Klempner SJ. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. J Gastrointest Oncol. 2018 Aug; 9(4):610-617. PMID: 30151257.
    Citations: 44     
  44. Klempner SJ, Gowen K, Lee TK, Zhu VW, Schrock AB, Miller VA, Ali SM, Ou SI. Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-a N848?K mutation. Lung Cancer. 2018 10; 124:86-89. PMID: 30268485.
    Citations:    Fields:    Translation:Humans
  45. Lin EM, Gong J, Klempner SJ, Chao J. Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond. World J Gastroenterol. 2018 Jul 07; 24(25):2686-2697. PMID: 29991874.
    Citations: 3     Fields:    Translation:Humans
  46. Schrock AB, Zhu VW, Hsieh WS, Madison R, Creelan B, Silberberg J, Costin D, Bharne A, Bonta I, Bosemani T, Nikolinakos P, Ross JS, Miller VA, Ali SM, Klempner SJ, Ou SI. Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol. 2018 09; 13(9):1312-1323. PMID: 29883838.
    Citations: 19     Fields:    Translation:Humans
  47. Chuang J, Gong J, Klempner SJ, Woo Y, Chao J. Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification. J Gastrointest Oncol. 2018 Jun; 9(3):560-572. PMID: 29998022.
  48. Sheikine Y, Pavlick D, Klempner SJ, Trabucco SE, Chung JH, Rosenzweig M, Wang K, Velcheti V, Frampton GM, Peled N, Murray M, Chae YK, Albacker LA, Gay L, Husain H, Suh JH, Millis SZ, Reddy VP, Elvin JA, Hartmaier RJ, Dowlati A, Stephens P, Ross JS, Bivona TG, Miller VA, Ganesan S, Schrock AB, Ou SI, Ali SM. BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. JCO Precis Oncol. 2018; 2. PMID: 32913992.
    Citations: 2     
  49. Klempner SJ, Chao J. Toward optimizing outcomes in Her2-positive gastric cancer: timing and genomic context matter. Ann Oncol. 2018 04 01; 29(4):801-802. PMID: 29462252.
    Citations: 3     Fields:    Translation:Humans
  50. Bhangoo MS, Boasberg P, Mehta P, Elvin JA, Ali SM, Wu W, Klempner SJ. Tumor Mutational Burden Guides Therapy in a Treatment Refractory POLE-Mutant Uterine Carcinosarcoma. Oncologist. 2018 05; 23(5):518-523. PMID: 29386312.
    Citations: 7     Fields:    Translation:Humans
  51. Schrock AB, Pavlick D, Klempner SJ, Chung JH, Forcier B, Welsh A, Young L, Leyland-Jones B, Bordoni R, Carvajal RD, Chao J, Kurzrock R, Sicklick JK, Ross JS, Stephens PJ, Devoe C, Braiteh F, Ali SM, Miller VA. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. Clin Cancer Res. 2018 04 15; 24(8):1881-1890. PMID: 29363525.
    Citations: 12     Fields:    Translation:HumansCells
  52. Klempner SJ, Mehta P, Schrock AB, Ali SM, Ou SI. Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature. Lung Cancer (Auckl). 2017; 8:241-247. PMID: 29255376.
    Citations: 3     
  53. Klempner SJ, Wu W, Mehta P, Schrock AB, Chao J, Ali SM. Genomic Profiling to Expand Management Options for Locally Advanced Esophagogastric Cancers: A Proof of Principle Case. JCO Precis Oncol. 2017; 1. PMID: 32913963.
  54. Dehal A, Graff-Baker AN, Vuong B, Fischer T, Klempner SJ, Chang SC, Grunkemeier GL, Bilchik AJ, Goldfarb M. Neoadjuvant Chemotherapy Improves Survival in Patients with Clinical T4b Colon Cancer. J Gastrointest Surg. 2018 02; 22(2):242-249. PMID: 28933016.
    Citations: 17     Fields:    Translation:Humans
  55. Tran PN, Taylor TH, Klempner SJ, Zell JA. The impact of gender, race, socioeconomic status, and treatment on outcomes in esophageal cancer: A population-based analysis. J Carcinog. 2017; 16:3. PMID: 28974922.
    Citations: 6     
  56. Kim ST, Klempner SJ, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim KM, Lee J. Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. Oncotarget. 2017 Sep 29; 8(44):77415-77423. PMID: 29100397.
    Citations: 26     Fields:    
  57. Mehta P, Hamid O, Klempner SJ. Pulse Dose Erlotinib and Zuckerguss Improvement in EGFR-Mutant NSCLC. J Thorac Oncol. 2017 12; 12(12):1857-1858. PMID: 28774860.
    Citations:    Fields:    Translation:Humans
  58. Tran PN, Sarkissian S, Chao J, Klempner SJ. PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence. Gastrointest Cancer. 2017; 7:1-11. PMID: 28757801.
    Citations: 18     
  59. Tran PN, Klempner SJ. ALK on my mind: alectinib takes an early lead in managing intracranial disease in non-small cell lung cancer with ALK rearrangements. Ann Transl Med. 2017 Apr; 5(7):173. PMID: 28480209.
    Citations: 2     
  60. Kim ST, Kim SY, Klempner SJ, Yoon J, Kim N, Ahn S, Bang H, Kim KM, Park W, Park SH, Park JO, Park YS, Lim HY, Lee SH, Park K, Kang WK, Lee J. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition. Ann Oncol. 2017 03 01; 28(3):547-554. PMID: 28028034.
    Citations: 15     Fields:    Translation:HumansCells
  61. Weinberg BA, Gowen K, Lee TK, Ou SI, Bristow R, Krill L, Almira-Suarez MI, Ali SM, Miller VA, Liu SV, Klempner SJ. Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers. Oncologist. 2017 02; 22(2):152-157. PMID: 28193735.
    Citations: 3     Fields:    Translation:Humans
  62. Tran PN, Klempner SJ. Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC. Front Med (Lausanne). 2016; 3:65. PMID: 27965961.
    Citations: 3     
  63. Ou SI, Schrock AB, Bocharov EV, Klempner SJ, Haddad CK, Steinecker G, Johnson M, Gitlitz BJ, Chung J, Campregher PV, Ross JS, Stephens PJ, Miller VA, Suh JH, Ali SM, Velcheti V. HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib. J Thorac Oncol. 2017 03; 12(3):446-457. PMID: 27903463.
    Citations: 20     Fields:    Translation:HumansCells
  64. Tran P, Nguyen C, Klempner SJ. Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes? Int Neurourol J. 2016 Nov; 20(Suppl 2):S131-140. PMID: 27915478.
    Citations: 12     
  65. Klempner SJ, Borghei A, Hakimian B, Ali SM, Ou SI. Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases. J Thorac Oncol. 2017 01; 12(1):152-156. PMID: 27693535.
    Citations: 19     Fields:    Translation:Humans
  66. Rankin A, Klempner SJ, Erlich R, Sun JX, Grothey A, Fakih M, George TJ, Lee J, Ross JS, Stephens PJ, Miller VA, Ali SM, Schrock AB. Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. Oncologist. 2016 Nov; 21(11):1306-1314. PMID: 27682134.
    Citations: 18     Fields:    
  67. Ou SI, Young L, Schrock AB, Johnson A, Klempner SJ, Zhu VW, Miller VA, Ali SM. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping. J Thorac Oncol. 2017 01; 12(1):137-140. PMID: 27666659.
    Citations: 31     Fields:    Translation:Humans
  68. Wei R, Chaurasia A, Yu S, Lall C, Klempner SJ. Focal Hepatic Fluorodeoxyglucose Uptake Mimics Liver Metastasis Following External Beam Radiation for Gastroesophageal Cancers: A Case and Review of the Literature. J Clin Imaging Sci. 2016; 6:30. PMID: 27625896.
  69. Connor M, Wei RL, Yu S, Sehgal V, Klempner SJ, Daroui P. Radiation dermatitis caused by a bolus effect from an abdominal compression device. Med Dosim. 2016; 41(3):221-4. PMID: 27264694.
    Citations: 1     Fields:    Translation:Humans
  70. Chao J, Lee J, Klempner SJ. Moving molecular subtypes to the clinic in gastric cancer. Transl Cancer Res. 2016 Jun; 5(Suppl 1):S25-S30. PMID: 28781963.
    Citations: 1     
  71. Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, Klempner SJ, Firozvi K, Frampton GM, Molina JR, Menon S, Brahmer JR, MacMahon H, Nowak J, Ou SH, Zauderer M, Ladanyi M, Zakowski M, Fischbach N, Ross JS, Stephens PJ, Miller VA, Wakelee H, Ganesan S, Salgia R. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. Oncologist. 2016 06; 21(6):762-70. PMID: 27245569.
    Citations: 33     Fields:    Translation:Humans
  72. Tran PN, Klempner SJ. Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer. Lung Cancer (Auckl). 2016; 7:91-97. PMID: 28210165.
    Citations: 3     
  73. Chung JH, Sanford E, Johnson A, Klempner SJ, Schrock AB, Palma NA, Erlich RL, Frampton GM, Chalmers ZR, Vergilio J, Rubinson DA, Sun JX, Chmielecki J, Yelensky R, Suh JH, Lipson D, George TJ, Elvin JA, Stephens PJ, Miller VA, Ross JS, Ali SM. Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. Ann Oncol. 2016 07; 27(7):1336-41. PMID: 27052656.
    Citations: 22     Fields:    Translation:HumansCells
  74. Klempner SJ, Gershenhorn B, Tran P, Lee TK, Erlander MG, Gowen K, Schrock AB, Morosini D, Ross JS, Miller VA, Stephens PJ, Ou SH, Ali SM. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy. Cancer Discov. 2016 06; 6(6):594-600. PMID: 27048246.
    Citations: 18     Fields:    Translation:HumansCells
  75. Ou SH, Weitz M, Jalas JR, Kelly DF, Wong V, Azada MC, Quines O, Klempner SJ. Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation. Lung Cancer. 2016 06; 96:15-8. PMID: 27133743.
    Citations: 5     Fields:    Translation:HumansPHPublic Health
  76. Wei RL, Jung BC, Manzano W, Sehgal V, Klempner SJ, Lee SP, Ramsinghani NS, Lall C. Bone mineral density loss in thoracic and lumbar vertebrae following radiation for abdominal cancers. Radiother Oncol. 2016 Mar; 118(3):430-6. PMID: 26993414.
    Citations: 12     Fields:    Translation:HumansPHPublic Health
  77. Lee J, Tran P, Klempner SJ. Targeting the MET Pathway in Gastric and Oesophageal Cancers: Refining the Optimal Approach. Clin Oncol (R Coll Radiol). 2016 08; 28(8):e35-44. PMID: 26880063.
    Citations: 5     Fields:    Translation:Humans
  78. Klempner SJ, Bordoni R, Gowen K, Kaplan H, Stephens PJ, Ou SH, Ali SM. Identification of BRAF Kinase Domain Duplications Across Multiple Tumor Types and Response to RAF Inhibitor Therapy. JAMA Oncol. 2016 Feb; 2(2):272-4. PMID: 26562024.
    Citations: 9     Fields:    Translation:HumansCells
  79. Kodityal S, Elvin JA, Squillace R, Agarwal N, Miller VA, Ali SM, Klempner SJ, Ou SH. A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib. Lung Cancer. 2016 Feb; 92:19-21. PMID: 26775591.
    Citations: 12     Fields:    Translation:Humans
  80. Le Rolle AF, Klempner SJ, Garrett CR, Seery T, Sanford EM, Balasubramanian S, Ross JS, Stephens PJ, Miller VA, Ali SM, Chiu VK. Identification and characterization of RET fusions in advanced colorectal cancer. Oncotarget. 2015 Oct 06; 6(30):28929-37. PMID: 26078337.
    Citations: 33     Fields:    Translation:Humans
  81. Raufi AG, Klempner SJ. Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. J Gastrointest Oncol. 2015 Oct; 6(5):561-9. PMID: 26487950.
    Citations: 25     
  82. Klempner SJ, Raufi A, Ou SH. Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning. Transl Lung Cancer Res. 2015 Oct; 4(5):649-52. PMID: 26629439.
    Citations: 1     
  83. Ou SH, Milliken JC, Azada MC, Miller VA, Ali SM, Klempner SJ. ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression. Lung Cancer. 2016 Jan; 91:70-2. PMID: 26464158.
    Citations: 16     Fields:    Translation:Humans
  84. Wang K, Johnson A, Ali SM, Klempner SJ, Bekaii-Saab T, Vacirca JL, Khaira D, Yelensky R, Chmielecki J, Elvin JA, Lipson D, Miller VA, Stephens PJ, Ross JS. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. Oncologist. 2015 Oct; 20(10):1132-9. PMID: 26336083.
    Citations: 30     Fields:    Translation:HumansCells
  85. Klempner SJ, Bazhenova LA, Braiteh FS, Nikolinakos PG, Gowen K, Cervantes CM, Chmielecki J, Greenbowe JR, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. Lung Cancer. 2015 Sep; 89(3):357-9. PMID: 26187428.
    Citations: 29     Fields:    Translation:Humans
  86. Klempner SJ, Ou SH. Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS. Chin Clin Oncol. 2015 Jun; 4(2):20. PMID: 26112806.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  87. Westin SN, Ju Z, Broaddus RR, Krakstad C, Li J, Pal N, Lu KH, Coleman RL, Hennessy BT, Klempner SJ, Werner HM, Salvesen HB, Cantley LC, Mills GB, Myers AP. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Mol Oncol. 2015 Oct; 9(8):1694-703. PMID: 26045339.
    Citations: 13     Fields:    Translation:HumansCells
  88. Ali SM, Sanford EM, Klempner SJ, Rubinson DA, Wang K, Palma NA, Chmielecki J, Yelensky R, Palmer GA, Morosini D, Lipson D, Catenacci DV, Braiteh F, Erlich R, Stephens PJ, Ross JS, Ou SH, Miller VA. Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. Oncologist. 2015 May; 20(5):499-507. PMID: 25882375.
    Citations: 32     Fields:    Translation:Humans
  89. Ou SH, Klempner SJ, Azada MC, Rausei-Mills V, Duma C. Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management. Lung Cancer. 2015 Jun; 88(3):355-9. PMID: 25882777.
    Citations: 11     Fields:    Translation:Humans
  90. Klempner SJ, Ou SH, Costa DB, VanderLaan PA, Sanford EM, Schrock A, Gay L, Ali SM, Miller VA. The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review. Clin Lung Cancer. 2015 Sep; 16(5):334-339.e1. PMID: 25911330.
    Citations: 12     Fields:    Translation:Humans
  91. Ou SH, Klempner SJ, Greenbowe JR, Azada M, Schrock AB, Ali SM, Ross JS, Stephens PJ, Miller VA. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib. J Thorac Oncol. 2014 Dec; 9(12):1821-5. PMID: 25393796.
    Citations: 30     Fields:    Translation:Humans
  92. Ostojic L, Klempner SA, Patel RA, Mitchell AA, Axler-DiPerte GL, Wurmbach E. Qualitative and quantitative assessment of single fingerprints in forensic DNA analysis. Electrophoresis. 2014 Nov; 35(21-22):3165-72. PMID: 25098234.
    Citations:    Fields:    Translation:HumansCells
  93. Klempner SJ, Aubin G, Dash A, Ou SH. Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment. Oncologist. 2014 Sep; 19(9):1008-10. PMID: 25096999.
    Citations: 9     Fields:    Translation:Humans
  94. Yang W, Raufi A, Klempner SJ. Targeted therapy for gastric cancer: molecular pathways and ongoing investigations. Biochim Biophys Acta. 2014 Aug; 1846(1):232-7. PMID: 24858418.
    Citations: 39     Fields:    Translation:HumansAnimalsCells
  95. Ignatius Ou SH, Azada M, Hsiang DJ, Herman JM, Kain TS, Siwak-Tapp C, Casey C, He J, Ali SM, Klempner SJ, Miller VA. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol. 2014 Apr; 9(4):549-53. PMID: 24736079.
    Citations: 54     Fields:    Translation:Humans
  96. Klempner SJ, Myers AP, Cantley LC. What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov. 2013 Dec; 3(12):1345-54. PMID: 24265156.
    Citations: 65     Fields:    Translation:HumansCells
  97. Klempner SJ, Myers AP, Mills GB, Westin SN. Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. Expert Opin Pharmacother. 2013 Nov; 14(16):2171-82. PMID: 23937415.
    Citations: 5     Fields:    Translation:Humans
  98. Li R, Klempner S. The effect of an enzymatic bone processing method on short tandem repeat profiling of challenged bone specimens. Leg Med (Tokyo). 2013 Jul; 15(4):171-6. PMID: 23384499.
    Citations: 1     Fields:    Translation:HumansCells
  99. Klempner SJ, Costa DB, Wu PA, Ariyabuddhiphongs KD. Safety of cupping during bevacizumab therapy. J Altern Complement Med. 2013 Aug; 19(8):729-31. PMID: 23379829.
    Citations: 1     Fields:    Translation:Humans
  100. Klempner SJ, Choueiri TK, Yee E, Doyle LA, Schuppan D, Atkins MB. Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients. J Clin Oncol. 2012 Sep 20; 30(27):e264-8. PMID: 22802316.
    Citations: 10     Fields:    Translation:Humans
  101. Klempner SJ, Bubley G. Complementary and alternative medicines in prostate cancer: from bench to bedside? Oncologist. 2012; 17(6):830-7. PMID: 22618569.
    Citations: 12     Fields:    Translation:HumansAnimals
  102. Selby KJ, Warner J, Klempner S, Konstantinopoulos PA, Hecht JL. Anti-Yo antibody associated with occult fallopian tube carcinoma. Int J Gynecol Pathol. 2011 Nov; 30(6):536-8. PMID: 21979588.
    Citations: 2     Fields:    Translation:Humans
  103. Klempner SJ, Cohen DW, Costa DB. ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers. J Thorac Oncol. 2011 Aug; 6(8):1439-40. PMID: 21847065.
    Citations: 6     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Klempner's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (278)
Co-Authors (51)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.